Alphamab Oncology (HKG:9966)
Hong Kong
· Delayed Price · Currency is HKD 10.64
-0.29 (-2.65%)
Apr 29, 2026, 4:08 PM HKT
Alphamab Oncology Revenue
In the year 2025, Alphamab Oncology had annual revenue of 566.24M CNY, down -11.54%. Alphamab Oncology had revenue of 246.80M in the half year ending December 31, 2025, with 199.84% growth.
Revenue
566.24M CNY
Revenue Growth
-11.54%
P/S Ratio
16.36
Revenue / Employee
1.14M CNY
Employees
498
Market Cap
10.31B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HBM Holdings | 1.23B |
| Lepu Biopharma | 1.04B |
| Everest Medicines | 1.90B |
| Abbisko Cayman | 681.17M |
| Shanghai Haohai Biological Technology | 2.73B |
| CARsgen Therapeutics Holdings | 139.84M |
| CStone Pharmaceuticals | 299.99M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
Alphamab Oncology News
- 4 months ago - Alphamab Oncology's JSKN033 Cleared For Phase 2 Cervical Cancer Trial By Chinese Regulatory Agency - Nasdaq